Clinical Trials Logo
  1. Home
  2. Pars Plana Vitrectomy
  3. NCT05013281
  4. Details
NCT05013281 Clinical Trial

Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy

Pars Plana Vitrectomy Clinical Trial

Official title:
Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05013281
Other study ID # TR2021SCH
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2010
Est. completion date January 28, 2021

Study information
Verified date July 2021
Source Beijing Tongren Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To analyze the characteristics, related risk factors, and prognosis of suprachoroidal hemorrhage (SCH) associated with pars plana vitrectomy (PPV).

Recruitment information / eligibility
Status Completed
Enrollment 28
Est. completion date January 28, 2021
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Suprachoroidal hemorrhage associated with pars plana vitrectomy Exclusion Criteria: - Patients with eye trauma-related Suprachoroidal hemorrhage were excluded.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Suprachoroidal hemorrhage associated with pars plana vitrectomy
SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.

Locations
Country Name City State
China Beijing Tongren Hospital Beijing Beijing

Sponsors (1)
Lead Sponsor Collaborator
Beijing Tongren Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary pathogenesis pathogenesis of PPV-related SCH and incidence of PPV-related SCH baseline
Secondary vision acuity the final vision acuity up to 7 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05990829 - Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial Phase 4
Recruiting NCT05631054 - Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
Recruiting NCT05728476 - Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema N/A
Recruiting NCT04774146 - Quantification of Silicone Oil Emulsification After Pars Plana Vitrectomy
Completed NCT04278079 - Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy N/A
Not yet recruiting NCT05592912 - Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities Phase 1
Completed NCT00548197 - Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Phase 1
Terminated NCT00936520 - SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy Phase 1
Recruiting NCT05248334 - A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy Phase 1